Ren Shiyan, Qian Songyi, Wang Wei, Liu Jiagtao, Liu Peng
Cardiovascular Surgery, China-Japan Friendship Hospital, the Chinese Ministry of Health, Beijing, China.
Ann Thorac Cardiovasc Surg. 2013;19(1):30-4. doi: 10.5761/atcs.oa.12.02061. Epub 2013 Jan 31.
To evaluate the effect of sarpogrelate for patients with atherosclerotic obliterans (ASO).
Patients with ASO were randomly divided into sarpogrelate group (n = 92) and control group (n = 84). The patients in sarpogrelate group received sarpogrelate (100 mg, tid), whereas in control group aspirin (100 mg, qd) was administered orally. The patients were followed up monthly to observe any side effect of medication. Clinical manifestation, painless walking distance, Rutherford type and ankle brachial Index (ABI) were studied.
In comparison with control group, the severity of pain, Rutherford type 0 and 1 were improved with statistic significance. Incidence of patients with intermittent claudication decreased from 56.6% before treatment to 28.3% after treatment; the painless walking distance was prolonged (116.3 ± 72.3m vs. 243.5 ± 175.3m, P <0.001); ABI values were increased (0.74 ± 0.17 vs. 0.86 ± 0.18; p <0.001). No side effect of medication was observed.
Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans.
